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Abstract
Background/Objective: Myelodysplastic syndrome (MDS) is a clonal disorder of hematopoietic stem cells, characterized
by ineffective hematopoiesis, peripheral cytopenias along with hypercellularity of the bone marrow, and marked
dysplastic features. Establishing MDS diagnosis is difﬁcult due to nonspeciﬁc clinical presentation and imprecise
morphological criteria. In anticipation to improve the diagnostic approach in this ﬁeld, we aimed to characterize the
clinical and morphological features of patients presented with cytopenias with a special focus on MDS.
Methods: We comprehensively reviewed all medical record of patients who were referred to the hematology laboratory
at KFSH-RC, Riyadh, Saudi Arabia, between January 2009 and March 2016 for evaluation of bone marrow aspirates and
trephine biopsies due to severe and persistent cytopenia(s) to rule out MDS.
Results: A total of 183 patients, 155 adult and 28 pediatric, were identiﬁed. In the adult group, MDS was diagnosed in 82
(52.9%) patients, with a male-to-female (M:F) ratio of 1.6:1 and mean age at diagnosis of 50 years. According to the World
Health Organization (WHO) 2017 criteria, MDS subtypes were as follows: MDS with single lineage dysplasia (SLD, 5%),
MDS with ring sideroblasts and SLD (MDS-RS-SLD 7%), MDS with multilineage dysplasia (MDS-MLD 21%), MDS
with deletion of chromosome 5q (MDS del(5q), 2%), MDS unclassiﬁable (MDS-U7%), hypoplastic MDS (h-MDS 4%),
MDS with excess blasts-1 (MDS-EB1, 20%), MDS with excess blasts-2 (MDS- EB2, 28%), and therapy-related MDS (6%).
Laboratory and morphological features were described. In both groups, cytogenetic abnormalities were classiﬁed according to the Revised International Prognostic Scoring System cytogenetic risk groups. In adults, the dominating cytogenetic abnormalities were monosomy 5 and monosomy 7 seen in 20.7% and 24.4% of patients, respectively. Peripheral
cytopenia not due to MDS was diagnosed in 54 (34.8%) patients, with a mean age of 43 years and M:F ratio of 1:1. The
cause of these cytopenias were as follows: bone marrow failure (BMF, 22%), peripheral destruction (20%), drug induced
(20%), anemia of chronic disease (16%), B12 deﬁciency (7%), infection (7%), paroxysmal nocturnal hemoglobinuria (4%),
idiopathic cytopenia of undetermined signiﬁcance (2%), and idiopathic dysplasia of undetermined signiﬁcance (2%). A
deﬁnite diagnosis of MDS was not possible in 19 patients due to insufﬁcient clinical data. In the pediatric group, MDS
was diagnosed in 14/28 (50%) patients, with M:F ratio of 1.8:1 and mean age at diagnosis of 4 years. MDS subtypes (WHO
2017) in 14 patients were as follows: refractory cytopenia of childhood (RCC, 42.8%), MDS-EB1 (42.8%), and MDS-EB2
(14.2%). Laboratory and morphological features were described. The prevalent cytogenetic abnormality was monosomy 7
in six/14 (42.8%) patients. Cytopenias due to other causes were diagnosed in eight/28 patients (28.5%), with a mean age of
6.5 years and M:F ratio of 1.6:1. The causes of non-MDS related cytopenia were: congenital BMF (4 patients), peripheral
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destruction (2 patients), immune deﬁciency (1 patient), and viral infection (1 patient). A deﬁnite diagnosis of MDS could
not be made in six/28 (21.4%) patients.
Conclusion: MDS is the cause of cytopenia in a signiﬁcant number of patients referred for evaluation of cytopenias,
appears at younger age, and tends to be more aggressive than that reported in international studies. Anemia, dysplastic
neutrophils in the peripheral blood, and dysplastic megakaryocytes in the bone marrow trephine biopsy are the most
reliable features in distinguishing MDS from other alternative diagnoses.
Keywords: Cytopenias, Myelodysplastic syndrome (MDS), Myelodysplastic syndrome

1. Introduction

M

yelodysplastic syndrome (MDS) is a clonal
disorder of hematopoietic stem cells, characterized by ineffective hematopoiesis, peripheral
cytopenias along with hypercellularity of the bone
marrow, and dysplastic features that could be
associated with variable cytogenetic and molecular
abnormalities causing bone marrow failure (BMF)
with a possible risk of evolution to acute myeloid
leukemia [1]. It usually affects older adults, with a
median age at diagnosis of 65 years and male
predominance [2]. Onset of the disease earlier than
the age of 50 years is unusual [3]. Rare cases of MDS
have been reported in children at a median age of
6 years [4]. In the United States, incidence of the
disease is estimated to be between 5.3 and 13.1 per
100,000 people [5], while in Japan, it varies between
1.2 and 2.5 per 100,000 people [6]. Few reported data
from Middle East are available [7e10]. Statistics
from Saudi Arabia are lacking.
Signs and symptoms of MDS at presentation are
nonspeciﬁc. Many patients are asymptomatic at
diagnosis and only come to the physician’s attention
based upon abnormalities found on routine blood
counts (e.g., anemia, neutropenia, and thrombocytopenia). Others present with symptoms or complications resulting from a previously unrecognized
cytopenia (e.g., infection and fatigue). Furthermore,
there is no precise morphological criteria for making
the diagnosis; dysplasia can be found in a wide
range of differential diagnoses such as in vitamin
B12 deﬁciency, viral infection, copper deﬁciency, or
zinc excess.

2. Materials and methods
We comprehensively reviewed all medical record
of patients who were referred to the hematology
laboratory at KFSH-RC, Riyadh, Saudi Arabia, between January 2009 and March 2016 for evaluation
of bone marrow aspirates and trephine biopsies due
to severe and persistent cytopenia(s) to rule out
MDS. The World Health Organization (WHO, 2017)

criteria for classiﬁcation and nomenclature of MDS
was applied.
2.1. Cytogenetic analysis
2.1.1. Karyotype
Bone marrow cells were processed for karyotype
analysis according to standard cytogenetic procedures. Heparinized bone marrow aspirate samples
were cultured overnight in 25 cm2 culture ﬂasks
(Falcon, USA) at 37 C and 5% CO2. After incubation, cultures were transferred to a 15 ml Falcon
conical tube and incubated for 1 hour with ethidium
bromide (Sigma-Aldrich), washed, and incubated
for 1 hour in an in-house prepared Cancer hypotonic solution all at 37 C. Followed by ﬁxation in 3
washes of 3:1 Carnoys ﬁxative (Methanol: Acetic
acid) followed by refrigeration. Slides are prepared
in a slide drying chamber (Thermotron, USA) aged
at 60 C for 2 hours then GTG banded (G band with
Trypsin - Giemsa, Sigma Aldrich). Analysis was
performed using the GENASIS (Applied Spectral
Imaging, USA) software platform. Chromosomal
abnormalities were identiﬁed and described according to the International System of Human Cytogenetic Nomenclature (ISCN) [11].
2.2. Fluorescence in situ hybridization
Circle slides of 18 mm were prepared from ﬁxed
cell suspensions obtained from standard harvest
procedures. Slides were aged in a 2x Saline-Sodium
Citrate (SSC) (Saline-Sodium Citrate) solution,
pretreated with pepsin A solution, and dehydrated
in a 70%, 85%, and 100% ethanol series. Slides and
the ﬂuorescently labeled DNA probe were co-denatured on Hybrite for 3 minutes at 73  C and hybridized overnight at 37  C. The next morning the
slides were washed in 0.4% SSC/0.3% NP40 solution
at 72  C, counterstained with 40 ,6-diamidino-2-phenylindole (DAPI) (40 ,6-diamidino-2-phenylindoleto)
visualize the nuclei, and analyzed by ﬂuorescent
microscopy. The current MDS ﬂuorescence in situ
hybridization (FISH) panel consists of the following
Abbott molecular (Vysis) probes: EGR1/D5S23
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(5q32/5p15.2), D7Z1/D7S522 (7cen/7q31), D7Z1/
D8Z2 (7cen/8cen), 20p/D20S108 (20q12), and RPN1/
MECOM (3q21/3q26).
2.3. Statistical analysis
Statistical analysis was performed using SPSS
version 20 (SPSS Inc., Chicago, IL, USA). Descriptive
statistics for the continuous variables are reported
as mean ± standard deviation, and categorical variables are summarized as frequencies and percentages. Categorical variables were compared using
chi-square test, and continuous variables were
compared using Student t test and ManneWhitney
U test. Hazard ratio was calculated to identify the
independent variables that contribute signiﬁcantly
to major outcomes. A p value of <0.05 was considered as the cut-off for signiﬁcance.

Fig. 1. Myelodysplastic syndrome subtypes. Note. del(5q) ¼ deletion of
chromosome 5q; EB1 and 2, excess blasts 1 and 2; h-MDS ¼ hypoplastic
myelodysplastic syndrome; MDS ¼ myelodysplastic syndrome; MDSU ¼ myelodysplastic syndrome unclassiﬁable; MLD ¼ multilineage
dysplasia; RS ¼ ringed sideroblasts; SLD ¼ single lineage dysplasia; TMDS ¼ therapy-related myelodysplastic syndrome.

3. Results
A total of 183 patients, 155 adult and 28 pediatric,
were identiﬁed from this review. In the adult group,
a diagnosis of MDS was conﬁrmed in 82 (52.9%)
patients, with the male-to-female (M:F) ratio of 1.6:1
and a mean age at diagnosis of 50 years. MDS subtypes according to the WHO 2017 criteria were as
follows: MDS with single lineage dysplasia (SLD,
5%), MDS with ring sideroblasts and SLD (7%), MDS
with multilineage dysplasia (21%), MDS with deletion of chromosome 5q (2%), MDS with excess
blasts-1 (EB1, 20%), MDS with excess blasts-2 (EB2,
27%), MDS unclassiﬁable (7%), hypoplastic MDS
(4%), and therapy-related MDS 6%, as shown in
Fig. 1. MDS group tended to have lower hemoglobin
(90 g; p < .001; hazard ratio [HR] 0.97; 95% conﬁdence interval [CI]: 0.96e0.98) than non-MDS group
(Table 1). In MDS group, the mean absolute
neutrophil count (ANC) was 2.17  109/L and the
mean platelet count was 32.51  109/L; these values
were comparable with those of non-MDS group
(Table 1). Morphological characteristics listed in
Table 2 indicate that peripheral blood neutrophils
show more evident dysplasia ( p < .001; HR 5.6; 95%
CI: 2.3e8.8), and the morphology of the bone
marrow trephine biopsy shows dysplastic megakaryocytes ( p < .001; HR 5; 95% CI: 1.7e8.2). Dyserythropoiesis,
dysgranulopoiesis,
and
dysmegakaryopoiesis were signiﬁcantly higher in
MDS group than in non-MDS group (70.4%, 79.3%,
59.8% vs. 51.8%, 25.9%, 22.2%, respectively), with
p < .001 and HR (95% CI) of 2.3 (1.3e3.3), 3.8
(1.9e5.6), and 2.8 (1.5e4.1), respectively. In the MDS
group, monosomy 5 and monosomy 7 were the most
frequent cytogenetic abnormalities found in 20.7%
and 24.4% patients, respectively; they were prevalent
in both high-grade MDS and therapy-related MDS,
while trisomy 8 and 20q12 were prevalent in lowgrade MDS and hypoplastic MDS (Fig. 2). Table 3
presents the Revised International Prognostic
Scoring System (IPSS-R) cytogenetic risk group
stratiﬁcation: very good risk (1.2%), good risk
(35.4%), intermediate risk (13.4%), poor risk (19.5%),
and very poor risk (13.4%). Fig. 3 illustrates the

Table 1. Clinical and laboratory features of myelodysplastic syndrome (MDS) versus non-MDS adult groups.
Group size, n
M:F ratio
Age, mean (SD), years
Hemoglobin, mean, g/dL
Absolute neutrophil count, mean, 109/L
Platelet count, mean, 109/L

MDS

Non-MDS

p; HR (95% CI)

82
1.6:1
50 (±18)
90
2.17
32.51

54
1:1
43 (±18)
104
4.47
29.32

0.035;
0.001;
0.167;
0.429;

Note. CI ¼ conﬁdence interval; F ¼ female; HR ¼ hazard ratio; M ¼ male; SD ¼ standard deviation.

1.02 (1.002e1.03)
0.97 (0.96e0.98)
0.91 (0.76e1.6)
1 (0.08e1.2)
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Table 2. Morphological features of myelodysplastic syndrome (MDS) versus non-MDS groups.
Dysplasia in peripheral blood
Dyserythropoiesis bone marrow aspirate
Dysgranulopoiesis bone marrow aspirate
Dysmegakaryopoiesis bone marrow aspirate
Dysplastic megakaryocytes in bone marrow trephine biopsy

Fig. 2. Results of ﬂuorescence in situ hybridization (FISH) in adult
patients with myelodysplastic syndrome. Note. EB1 and 2, excess blasts
1 and 2; h-MDS ¼ hypoplastic myelodysplastic syndrome; MDS ¼
myelodysplastic syndrome; MDS-U ¼ myelodysplastic syndrome unclassiﬁable; MLD ¼ multilineage dysplasia; RS ¼ ringed sideroblasts;
SLD ¼ single lineage dysplasia; T-MDS ¼ therapy-related myelodysplastic syndrome.

Table 3. Revised international prognostic scoring system cytogenetic risk
groups.
Very good
Good
Intermediate
Poor
Very poor

Saudi (%)

Japan (%)

Caucasian (%)

1.2
35.4
13.4
19.5
13.4

1
71.3
17
4.3
6.3

3.6
72.2
13.3
4.1
6.9

MDS (%)

Non-MDS (%)

p; HR (95% CI)

84.9
70.4
79.4
59.8
83.3

14.81
51.85
25.93
22.22
14.81

0.001;
0.001;
0.001;
0.001;
0.001;

5.6 (2.3e8.8)
2.3 (1.3e3.3)
3.8 (1.9e5.6)
2.8 (1.5e4.1)
5 (1.7e8.2)

In the pediatric group, the results were only
descriptive due to the small sample size (Table 4).
MDS was diagnosed in 14/28 (50%) patients, with a
mean age of 4 years and M:F ratio of 1.8:1. MDS
subtypes (WHO 2017) were as follows: six/14 (42.8%)
refractory cytopenia of childhood (RCC), six/14
(42.8%) MDS-EB1, and two/14 (14.2%) MDS-EB2.
The dominating cytogenetic abnormality was
monosomy 7 found in six/14 (42.8%) patients.
Another two patients (25%) had a complex karyotype. Two/14 patients showed aberrations involving
chromosome 12p by FISH, one with loss of 12p13
and one with a rearrangement involving ETV6
(12p13), but a normal karyotype. Normal cytogenetics were found in ﬁve/14 (35.7%) patients. Cytogenetic abnormalities were classiﬁed according to
IPSS-R cytogenetic risk group as following: good
risk six/14 (42.8%), intermediate risk one/14 (7.2%),
and poor risk seven/14 (50%) (Fig. 4). MDS was de
novo in 10/14 (71.4%) patients and secondary to
congenital BMF in four/14 (28.6%) patients. Cytopenia due to other causes was diagnosed in eight/28
(28.5%) patients, with a mean age of 6.5 years and
M:F ratio of 1.6:1. The causes of cytopenia were as
following: congenital BMF (4 patients), peripheral
destruction (2 patients), immune deﬁciency (1 patient), and viral infection (1 patient). A deﬁnite
diagnosis of MDS could not be made for six/28
(21.4%) patients.

4. Discussion

Fig. 3. Diagnosis of non-myelodysplastic syndrome group. Note.
BM ¼ bone marrow; ICUS ¼ idiopathic cytopenia of undetermined
signiﬁcance; IDUS ¼ idiopathic dysplasia of undetermined signiﬁcance;
PNH ¼ paroxysmal nocturnal hemoglobinuria.

reasons for peripheral cytopenia that were not due to
MDS. Despite suspicious morphology, a deﬁnite
diagnosis of MDS was not possible in 19 patients due
to insufﬁcient clinical data and normal cytogenetics.

To the best of our knowledge, this is the ﬁrst study
in Saudi Arabia that addresses clinical, morphological, and cytogenetic features of MDS. The onset of
MDS at a younger age has been more frequently reported in Asian countries, including Japan, China,
Korea, India, Thailand, and Turkey, with the median
age of patients reported between 40 and 50 years; this
is one to two decades younger than that of patients in
Western countries [12]. These ﬁndings were also
conﬁrmed in our study. Environmental pollutions
and/or other factors, including uncontrolled pesticide
use, may contribute to these differences [12].
The presence of at least one cytopenia is a “sine
qua non” for any MDS diagnosis; the thresholds are
hemoglobin < 10 g/dL, platelet count < 100  109/L,
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Table 4. Clinical and laboratory features of myelodysplastic syndrome (MDS) versus non-MDS pediatric groups.
MDS

Non-MDS

Group size, n

14 6 RCC
- 6 MDS-EB1
- 2 MDS-EB2

Mean age, years
M:F ratio
Hemoglobin, mean, g/dL
Absolute neutrophil count, mean, 109/L
Platelet count, mean, 109/L

4
1.8:1
72.5
0.3258
88.5

8- 4 congenital bone marrow failure
- 2 peripheral destruction
- 1 immune deﬁciency
- 1 viral infection
6.5
1.6:1
79.7
2.1
197.8

Note. EB1 ¼ excess blasts-1; EB2 ¼ excess blasts-2; F ¼ female; M ¼ male; RCC ¼ refractory cytopenia of childhood.

Fig. 4. Revised International Prognostic Scoring System (IPSS-R) cytogenetic risk groups for pediatric patients.

and ANC < 1.8  109/L [13]. Our ﬁndings suggest
that among those parameters, anemia with a hemoglobin level < 90 g/dl ( p < .001) is the most
reliable indicator for making the diagnosis.
Morphological abnormalities in red blood cells
(RBCs) is usual, including the presence of circulating nucleated RBCs with stigmata of dyserythropoiesis. Dysgranulopoiesis in neutrophils is
variably observed, from absent to severe, and can
involve both the nucleus and cytoplasm. The nucleus can show abnormal lobulation and/or an
abnormal chromatin pattern, while the cytoplasm
can show abnormalities in granule size (pseudoCh
ediakeHigashi) and/or content (hypogranular or
agranular cytoplasm). Abnormal topographic distribution of the megakaryocytes in the bone marrow
trephine biopsy along with features of dysmegakaryopoiesis in bone marrow aspirate, such as
multinuclearity, nuclear hypolobulation, and the
presence of micromegakaryocytes, are frequently
observed in MDS [14]. Our study showed that when
dysplastic features are present in the peripheral
blood, the diagnosis of MDS is likely if there is high
index of clinical suspicion ( p < .001, HR 5.6). It also
emphasizes the importance of the bone marrow
trephine biopsy not only for structural assessment

but also for morphological evaluation of megakaryocytes to support the diagnosis ( p < .001, HR 5).
For MDS sub-classiﬁcation, our patients tended to
have more aggressive presentation than the
Caucasian and Japanese cohorts (Table 3). Highgrade MDS accounted for 45% in our patients
compared with 36.4% in Caucasians and 31.8% in
Japanese. Del(5q) accounted for 2% in our patients
compared with 1.3% in Japanese and 4.7% in Caucasians [15]. When we applied the WHO 2016 subclassiﬁcation on the retrospective review, we took
into consideration the changes made in the criteria
for diagnosis of acute erythroid leukemia. Subsequently, two patients initially diagnosed as acute
erythroid leukemia were reclassiﬁed as MDS-EB.
Regarding the cytogenetic abnormalities, monosomy 5 and monosomy 7 were the most frequent
abnormalities, being prominent in high-grade and
therapy-related MDS. The percentage of MDS with
normal cytogenetics was signiﬁcantly lower in our
patients (32.9%) than in Japanese (65.3%) and
Caucasian (62.7%) cohorts. One explanation for
these differences is that most of the high-grade
MDS are referred to our center for stem cell transplant. The distribution of IPSS-R cytogenetic risk
group was higher in poor and very poor risk groups
when compared with the frequency in Japanese and
Caucasians [15] (Table 3). The IPSS-R classiﬁcation
was not obtained for 17% of patients due to unavailable genetic data.
The number of pediatric patients was relatively
small to draw a statistically signiﬁcant conclusion.
However, the collected data are comparable with a
previously published data [16], from King Faisal
Specialist Hospital & Research Center between 1993
and 2008, where the mean age was 4.8 years
compared with 4 years in our data. Furthermore,
RCC was diagnosed in 64% of patients in the previous data compared with 42.8% patients in our
data. High-grade MDS has increased compared
with the previous data; MDS-EB was diagnosed in
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36% of patients compared with 57% of patients in
our data. The presence of monosomy 7 was higher
in our data than in the previous data (42.8% vs. 35%)
[16].
In conclusion, MDS is the cause of cytopenia(s) in
a signiﬁcant number of patients, appears at a
younger age, and tends to be more aggressive than
that reported in international studies. Anemia,
dysplastic neutrophils in the peripheral blood, and
dysplastic megakaryocytes in the bone marrow
trephine biopsy are the most reliable features in
distinguishing MDS from an alternative diagnosis.
We recommend future large-scale multicentric
studies to include larger number of patients with
molecular genetic data for better characterization of
this disease entity in the Saudi population.
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